AIM
GENE

Acrospire Investment Management’s Genetic Technologies Ltd. GENE Stock Holding History

Acrospire Investment Management’s Portfolio GENE Stock Details GENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-361
Closed -$7K – 1547
2017
Q2 		$7K Buy
+361
New +$7.56K 0.01% 1896

Other funds holding GENE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Acrospire Investment Management's GENE Position: Q3 2017 in Review

Acrospire Investment Management sold out of Genetic Technologies Ltd. (GENE) in Q3 2017, closing a stake of 361 shares — an estimated $7K sold.

Acrospire Investment Management first reported a position in GENE in Q2 2017 and held it in 1 quarter. The position peaked at $7K in Q2 2017. 10 funds tracked by Wall St. Rank hold GENE as of Q3 2017.

  • Acrospire Investment Management reported no remaining Genetic Technologies Ltd. position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 361 Genetic Technologies Ltd. shares in Q3 2017, an estimated $7K.
  • Acrospire Investment Management first reported a position in Genetic Technologies Ltd. in Q2 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Genetic Technologies Ltd. position peaked at $7K in Q2 2017.
  • 10 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.